SCHEMBL25844189

SCHEMBL25844189

COc1cc(-c2cn(C)c(=O)c3[nH]ncc23)cc(Cl)c1C(=O)N1CCC(C(C)C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 7/20 0.39
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
KCNH2 Q12809 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TP53 P04637 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
BRD9 Q9H8M2 7/20 0.35
BRD7 Q9NPI1 4/20 0.34
TGFBR1 P36897 2/20 0.34
ACVR1 Q04771 2/20 0.34
TAF1 P21675 1/20 0.34
BRPF1 P55201 1/20 0.34
BPTF Q12830 1/20 0.34
TAF1L Q8IZX4 1/20 0.34
CREBBP Q92793 1/20 0.34
CECR2 Q9BXF3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23798959 0.91 BRD4 (0.38) BRD4CYP3A4CYP2C19KCNH2KDM4E
SCHEMBL25091765 0.90 BRD4 (0.42) BRD4CYP3A4CYP2C19KCNH2KDM4E
SCHEMBL25844196 0.90 ACVR1 (0.41) BRD4KCNH2KDM4EALDH1A1TP53
SCHEMBL23797637 0.85 BRD4 (0.48) BRD4CYP3A4CYP2C19KCNH2KDM4E
SCHEMBL25091864 0.85 BRD9 (0.51) BRD4CYP3A4CYP2C19KCNH2KDM4E
SCHEMBL25844193 0.85 BRD4 (0.44) BRD4KDM4EALDH1A1TP53KMT2A
SCHEMBL25091100 0.84 BRD4 (0.46) BRD4CYP3A4CYP2C19KCNH2KDM4E
SCHEMBL25091531 0.83 BRD4 (0.42) BRD4CYP3A4CYP2C19KCNH2ALDH1A1
SCHEMBL25091944 0.82 ACVR1 (0.43) BRD4KDM4EALDH1A1BRD9BRD7
SCHEMBL23783109 0.81 BRD9 (0.39) BRD4BRD9BRD7TGFBR1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 BRD4 17/4885CYP3A4 4753/4885CYP2C19 4395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.